Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial  Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington,

Published byΚρίος Λόντος Modified over 5 years ago

Similar presentations

Presentation on theme: "Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial  Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington,"— Presentation transcript:

1 Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial 
Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington, BSc, Peter J. Franks, PhD, Roger Greenhalgh, MA, MD, MCh, FRCS  Journal of Vascular Surgery  Volume 13, Issue 1, Pages (January 1991) DOI: / (91)90022-M Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

2 Fig. 1 The rate of graft failure expressed per 1000 patient-months at risk demonstrates that most grafts failed in the first 12 months with the peak failure rate in the first 3 months being 43/1000 patient-months, which fell to under 10/1000 in subsequent years. Journal of Vascular Surgery  , DOI: ( / (91)90022-M) Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

3 Fig. 2 Graft patency was measured objectively and plotted by use of life-table methods comparing patients randomized to ASA + DPM and placebo. An apparent improvement in patency over the first 2 years with ASA + DPM is lost by 3 years, and the overall difference does not achieve statistical significance (p = 0.43). Journal of Vascular Surgery  , DOI: ( / (91)90022-M) Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

4 Fig. 3 Analysis of the traditional risk factors for femoropopliteal graft patency by means of the life-table method failed to demonstrate an important influence of (A) distal anastamosis above or below the knee or (B) indication for arterial reconstruction. The severity of arterial disease at the distal anastamosis recorded by the operating surgeon (C) was significantly associated with subsequent graft performance (p = 0.038). The participating surgeons used reversed or in situ techniques for vein bypass according to their preference, and this choice had no effect on subsequent patency (D). Journal of Vascular Surgery  , DOI: ( / (91)90022-M) Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

5 Fig. 3 Analysis of the traditional risk factors for femoropopliteal graft patency by means of the life-table method failed to demonstrate an important influence of (A) distal anastamosis above or below the knee or (B) indication for arterial reconstruction. The severity of arterial disease at the distal anastamosis recorded by the operating surgeon (C) was significantly associated with subsequent graft performance (p = 0.038). The participating surgeons used reversed or in situ techniques for vein bypass according to their preference, and this choice had no effect on subsequent patency (D). Journal of Vascular Surgery  , DOI: ( / (91)90022-M) Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

6 Fig. 4 Overall mortality rate in these patients was high, and although reduced by 13% on ASA + DPM this difference has failed to achieve statistical significance (p = 0.14). Journal of Vascular Surgery  , DOI: ( / (91)90022-M) Copyright © 1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Download ppt "Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial  Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington,"

Similar presentations

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD 

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD 
A review of 100 consecutive reconstructions of the distal vertebral artery for embolic and hemodynamic disease  Ramon Berguer, MD, PhD, Mark D. Morasch,

A review of 100 consecutive reconstructions of the distal vertebral artery for embolic and hemodynamic disease  Ramon Berguer, MD, PhD, Mark D. Morasch,
Improved graft patency and altered remodeling in infrainguinal vein graft reconstruction for aneurysmal versus occlusive disease  Gilbert R. Upchurch,

Improved graft patency and altered remodeling in infrainguinal vein graft reconstruction for aneurysmal versus occlusive disease  Gilbert R. Upchurch,
John Blebea, MD, Kenneth Ouriel, MD, Richard M. Green, MD, William M

John Blebea, MD, Kenneth Ouriel, MD, Richard M. Green, MD, William M
Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial  Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington,

Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial  Charles McCollum, MB, ChB, MD, FRCS, Christine Alexander, Dip N, Glenda Kenchington,
Richard M. Green, MD, William M

Richard M. Green, MD, William M
Late survival in abdominal aortic aneurysm patients: The role of selective myocardial revascularization on the basis of clinical symptoms  Martha M. Reigel,

Late survival in abdominal aortic aneurysm patients: The role of selective myocardial revascularization on the basis of clinical symptoms  Martha M. Reigel,
Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease  Joseph P. Archie, PhD, MD  Journal of Vascular.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease  Joseph P. Archie, PhD, MD  Journal of Vascular.
Lloyd M. Taylor, M.D., Edward S. Phinney, M.D., John M. Porter, M.D. 

Lloyd M. Taylor, M.D., Edward S. Phinney, M.D., John M. Porter, M.D. 
Pedal bypass versus tibial bypass with autogenous vein: A comparison of outcome and hemodynamic results  Joseph R. Schneider, MD, PhD, Daniel B. Walsh,

Pedal bypass versus tibial bypass with autogenous vein: A comparison of outcome and hemodynamic results  Joseph R. Schneider, MD, PhD, Daniel B. Walsh,
A new valvulotome for in situ bypass grafts

A new valvulotome for in situ bypass grafts
Axillofemoral bypass: A tool with a limited role

Axillofemoral bypass: A tool with a limited role
Multilevel data analysis: What? Why? How?

Multilevel data analysis: What? Why? How?
Malcolm O. Perry, MD, Richard Kempczinski, MD 

Malcolm O. Perry, MD, Richard Kempczinski, MD 
Durability of the in situ saphenous vein arterial bypass: A comparison of primary and secondary patency  Dennis F. Bandyk, M.D., Hermann W. Kaebnick,

Durability of the in situ saphenous vein arterial bypass: A comparison of primary and secondary patency  Dennis F. Bandyk, M.D., Hermann W. Kaebnick,
Andrea Mingoli, MD, Paolo Sapienza, MD, Richard J

Andrea Mingoli, MD, Paolo Sapienza, MD, Richard J
Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: Do the results justify an attempt before bypass grafting?  Richard.

Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: Do the results justify an attempt before bypass grafting?  Richard.
Return to well-being and function after infrainguinal revascularization  Gary W. Gibbons, MD, Anne M. Burgess, RN, Edward Guadagnoli, PhD, Frank B. Pomposelli,

Return to well-being and function after infrainguinal revascularization  Gary W. Gibbons, MD, Anne M. Burgess, RN, Edward Guadagnoli, PhD, Frank B. Pomposelli,
Does the in situ technique for autologous vein femoropopliteal bypass offer any hemodynamic advantage?  Jonathan D. Beard, F.R.C.S., Richard E. Lee, F.R.C.S.,

Does the in situ technique for autologous vein femoropopliteal bypass offer any hemodynamic advantage?  Jonathan D. Beard, F.R.C.S., Richard E. Lee, F.R.C.S.,
Walter J. McCarthy, MD, William H. Pearce, MD, William R

Walter J. McCarthy, MD, William H. Pearce, MD, William R

Similar presentations

Ads by Google